17S-FD-895: An Improved Synthetic Splice Modulator mirroring FD-895
FDGLY offers the following improvements over known splicing modulators:Improved stability: unlike most of the natural product and synthetic derivatives designed to date FDGLY is bench stable. Easier synthetic preparation: the core unit of FDGLY is prepared from D-glucose streamlining the synthetic preparation. Potent activity in mammalian cell models: properties can be tuned to deliver unique splicing modulatory patterns. Readily addressed medicinal chemical optimization: the use of D-glucose has allowed analog developed to rapidly proceed using other carbohydrate building blocks. The potential for targeting the splicing of specific genes: the carbohydrate motif allows this derivative, unlike any analog to date, to be subjected to detailed optimization of activity that targets specific genes.
FDGLY can be potentially used as a therapeutic agent in clinical use against cancer, as well as an agent to potentiate the effects of known cancer agents. An additional use would be for research, as a molecular probe to modulate splicing.
Researchers from UC San Diego have designed a stable splice modulator with improved pharmacological properties. This new analog, described herein as FDGLY, provides several benefits over the known natural product based splice modulators including spliceostatins, pladienolides, and herboxidiene, as well as the current synthetic derivatives approaching or reached IND status including 17S-FD-895, E7107 or 6-deoxypladienolide B. FDGLY is a fully-synthetic spliceosome modulator that mirrors the structural features of FD-895. While FD-895 displays poor pharmacological stability (a factor common to nearly all semi-synthetic or synthetically-derived splice modulators to date), FDGLY displays improved stability in pharmacological buffers, plasma, cell lysates and animal models.
State Of Development The synthesis of FDGLY has been completed and is currently being used in cell and animal models to complete pharmacological and activity studies. In addition, medicinal chemical efforts are being explored for translation into the clinic for the treatment of cancer. The use of FDGLY is being used to potentiate already known chemotherapeutic agents by using FDGLY to reduce the levels of the proteins targeted by known chemotherapeutics within targeted tumor cells. Intellectual Property Info A provisional patent has been submitted and the technology is available to license. Related Materials Dhar S, La Clair JJ, León B, Hammons JC, Yu Z, Kashyap MK, Castro JE, Burkart MD. A Carbohydrate-Derived Splice Modulator. J Am Chem Soc. 2016 Apr 20;138(15):5063-8. Tech ID/UC Case 28845/2016-131-0 Related Cases 2016-131-0
Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CHM. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell. 2016 Nov 3;19(5):599-612.
USA
